COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medicines Agency’s human medicines committee.
(Reporting by Stine Jacobsen, eiditn by Anna Ringstrom)
